Compare Anheuser-Busch Inbev SA (BUD) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs Nuvalent Inc — how do they compare? Anheuser-Busch Inbev SA trades at $79.7 (market cap $153.45B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Anheuser-Busch Inbev SA is far larger — about 15.6× Nuvalent Inc's market cap, and Anheuser-Busch Inbev SA pays a 1.7% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| BUD | NUVL | |
|---|---|---|
Market Cap | $153.45B | $9.81B |
Sector | Consumer Staples | Technology |
52-Week High | $85.09 | $123.96 |
52-Week Low | $57.10 | $72.16 |
Enterprise Value | $214.64B | $8.52B |
Dividend Yield | 1.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $79.33, down 0.35% with bearish technical signals. The company demonstrates solid fundamentals with consistent earnings beats, 11.9% net margin, and improving cash flow. Recent dividend payment of $1.17 and positive analyst sentiment with 57.8% buy ratings support the investment case. Premiumization strategy and digital expansion drive growth amid changing consumer preferences.
Outlook remains positive with $90.08 consensus price target offering 13.5% upside. Key risks include alcohol moderation trends and competitive pressures. Strong balance sheet with declining debt-to-asset ratio to 33.9% provides financial stability. Revenue growth expected to accelerate to $61B in 2026 with expanding margins.
Nuvalent (NUVL) trades at $123.94, showing minimal daily movement with a 0.03% gain. The stock is in focus following GSK's proposed acquisition at $124 per share, announced June 2026. Technically, the price is at the acquisition offer level with a bullish moving average signal but overbought RSI readings. Fundamentally, the company reports significant losses with negative ROE and ROA, while cash flow remains supported by financing activities.
The investment outlook is dominated by the pending acquisition, limiting upside beyond the offer price. Key risks include deal completion uncertainty and ongoing operational losses. Analyst sentiment is mixed with a slight hold bias, reflecting caution until transaction closure. Shareholder value hinges on successful deal execution amid financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
